Business Insider
My Markets Watchlist
Markets Stocks

Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv Stock , MIRM

50.38 -0.42 -0.83%
03:59:59 PM EDT 6/20/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/20/2025 the closing price of the Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv share was $50.80 on BTT. Compared to the opening price on Friday 06/20/2025 on BTT of $51.20, this is a drop of 0.79%. Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv's market capitalization is $2.04 B by 49.53 M shares outstanding.
Is Mirum Pharmaceuticals stock a Buy, Sell or Hold? Mirum Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 45 buy ratings, 6 hold ratings, and 0 sell ratings.
What was the 52-week low for Mirum Pharmaceuticals stock? The low in the last 52 weeks of Mirum Pharmaceuticals stock was 28.56. According to the current price, Mirum Pharmaceuticals is 176.40% away from the 52-week low.
What was the 52-week high for Mirum Pharmaceuticals stock? The high in the last 52 weeks of Mirum Pharmaceuticals stock was 54.18. According to the current price, Mirum Pharmaceuticals is 92.99% away from the 52-week high.
What are analysts forecasts for Mirum Pharmaceuticals stock? The 51 analysts offering price forecasts for Mirum Pharmaceuticals have a median target of 60.20, with a high estimate of 84.00 and a low estimate of 35.00. The median estimate represents a 83.69 difference from the last price of 50.38.

Mirum Pharmaceuticals Stock Snapshot

43.23
Bid
100.00
Bid Size
57.22
Ask
100.00
Ask Size
6/20/2025
Date
3:59 PM
Time
11,995.00
Volume
50.80
Prev. Close
51.20
Open
2.49 B
Market Cap in USD
49.53 M
Number of Shares
49.53 M
Total Number of Shares
49.68
Day Low
51.37
Day High
50.38
28.56
52 Week Low
54.18
52 Week High
50.38
0.00
Dividend in USD
0.00
Dividend Yield
80.82
Free Float in %
-1.85
EPS in USD
4.67
Book Value per Share in USD
0.22
Cash Flow per Share in USD

Historical Prices for Mirum Pharmaceuticals

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Mirum Pharmaceuticals Analyst Data

Total Analysts: 51
Buy Ratings: 45 Neutral Ratings: 6 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 35.00 Median: 60.20 Highest: 84.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Mirum Pharmaceuticals Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/19/25 H.C. Wainwright & Co.
Maintained Buy $73
05/13/25 Raymond James Financial, Inc.
Maintained Buy $77
05/09/25 JMP Securities LLC
Maintained Buy $76
02/28/25 H.C. Wainwright & Co.
Maintained Buy $72
02/27/25 Baird Patrick & Co
Maintained Buy $55
07/26/24 H.C. Wainwright & Co.
Maintained Buy $66
07/08/24 H.C. Wainwright & Co.
Maintained Buy $66
06/28/24 H.C. Wainwright & Co.
Maintained Buy $66
06/20/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $66
06/18/24 Citigroup Corp.
Maintained Buy $64
06/18/24 J.P. Morgan
Maintained Buy $39
06/18/24 Morgan Stanley
Maintained Buy $57
06/18/24 JMP Securities LLC
Maintained Buy $68
06/17/24 H.C. Wainwright & Co.
Maintained Buy $66
06/17/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $48
06/17/24 Baird Patrick & Co
Maintained Buy $39
06/07/24 H.C. Wainwright & Co.
Maintained Buy $58
06/03/24 H.C. Wainwright & Co.
Maintained Buy $58
05/10/24 Morgan Stanley
Maintained Buy $53
05/09/24 JMP Securities LLC
Maintained Buy $66
05/09/24 Citigroup Corp.
Maintained Buy $38
05/09/24 Cantor Fitzgerald
Maintained Buy $40
05/09/24 H.C. Wainwright & Co.
Maintained Buy $58
04/17/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $48
04/02/24 H.C. Wainwright & Co.
Maintained Buy $58
03/14/24 JMP Securities LLC
Maintained Buy $72
03/14/24 H.C. Wainwright & Co.
Maintained Buy $58
03/04/24 Cantor Fitzgerald
Maintained Buy $40
02/29/24 H.C. Wainwright & Co.
Maintained Buy $45
02/29/24 JMP Securities LLC
Maintained Buy $69
02/29/24 Cantor Fitzgerald
Maintained Buy $35
01/11/24 JMP Securities LLC
Maintained Buy $64
12/19/23 Raymond James Financial, Inc.
Maintained Buy $64
12/18/23 H.C. Wainwright & Co.
Maintained Buy $58
11/27/23 Cantor Fitzgerald
Maintained Buy $50
11/20/23 J.P. Morgan
Maintained Buy $37
11/15/23 Cantor Fitzgerald
Maintained Buy $50
11/13/23 Morgan Stanley
Maintained Buy $60
11/03/23 H.C. Wainwright & Co.
Maintained Buy $60
10/24/23 Cantor Fitzgerald
Maintained Buy $50
10/18/23 JMP Securities LLC
Maintained Buy $70
10/18/23 Raymond James Financial, Inc.
Maintained Buy $77
10/17/23 Evercore
Maintained Buy $62
10/09/23 JMP Securities LLC
Maintained Buy $70
09/20/23 JMP Securities LLC
Maintained Buy $70
09/13/23 H.C. Wainwright & Co.
Maintained Buy $63
08/21/23 Raymond James Financial, Inc.
Maintained Buy $84
08/04/23 H.C. Wainwright & Co.
Maintained Buy $63
08/04/23 Raymond James Financial, Inc.
Maintained Buy $79
07/18/23 H.C. Wainwright & Co.
Maintained Buy $63

Mirum Pharmaceuticals Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 446 522 630 761 882
Dividend 0.00 0.00 0.00 - -
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % - -
EPS -1.11 -0.49 - 1.39 2.72
P/E Ratio -45.26 -103.44 67.15 36.24 18.52
EBIT -59 -28 41 118 217
EBITDA -38 0 53 - -
Net Profit -57 -25 42 111 218
Net Profit Adjusted -48 -15 42 - -
Pre-Tax Profit -54 -26 43 121 233
Pre-Tax Profit Reported -55 -23 47 - -
EPS (Non-GAAP) ex. SOE -1.14 -0.46 0.75 - -
EPS (GAAP) -1.05 -0.30 - - -
Gross Income 347 399 504 539 626
Cash Flow from Investing -6 - - - -
Cash Flow from Operations 36 - - - -
Cash Flow from Financing 10 0 0 - -
Cash Flow per Share 0.69 1.44 2.32 - -
Free Cash Flow 34 72 145 - -
Free Cash Flow per Share - - - - -
Book Value per Share 4.82 5.84 8.17 - -
Net Debt -108 -180 -321 - -
Research & Development Exp. 175 184 189 175 182
Capital Expenditure 12 1 1 - -
Selling, General & Admin. Exp. 236 258 278 307 312
Shareholder’s Equity - - - - -
Total Assets 709 780 - - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 9 9 10 10
Average Estimate - -0.331 USD -0.282 USD -1.113 USD -0.487 USD
Year Ago - -0.522 USD -0.298 USD -1.851 USD -
Publish Date - 7/31/2025 11/12/2025 - -
Revenue Estimates
No. of Analysts - 8 8 9 9
Average Estimate - 107 USD 112 USD 446 USD 522 USD
Year Ago - 78 USD 90 USD 337 USD -
Publish Date - 7/31/2025 11/12/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 336.89 186.37 77.06 19.14 0.00 0.00 0.00
Change of sales in % 80.76 141.85 302.66 - - - -
Gross profit on sales 254.72 139.01 64.35 16.90 -0.62 -0.32 0.00
Gross profit on sales change in % 83.24 116.02 280.77 - -92.28 - -
Operating income -87.61 -109.15 -131.22 -173.41 -104.30 -54.74 -2.92
Operating income change in % 19.74 16.82 24.33 -66.27 -90.52 -1,777.33 -
Income before tax -86.91 -162.42 -142.07 -83.95 -103.26 -52.53 -17.35
Income before tax change in % 46.49 -14.33 -69.23 18.70 -96.57 -202.81 -
Income after tax -87.94 -163.42 -135.67 -83.99 -103.27 -52.55 -17.35
Income after tax change in % 46.18 -20.45 -61.53 18.67 -96.51 -202.93 -

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 445.11 397.95 210.87 174.44 68.77 16.36 2.45
Long-term liabilities per share 6.59 6.65 3.95 4.31 1.69 0.14 0.00
Equity 225.64 248.67 142.04 120.21 172.10 130.35 49.53
Equity change in % -9.26 75.07 18.16 -30.15 32.03 - -
Balance sheet total 670.75 646.62 352.91 294.65 240.86 146.71 51.98
Balance sheet total change in % 3.73 83.23 19.77 22.33 64.17 182.27 -

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 7.09 4.56 2.28 0.63 0.00 0.00 0.00
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 -
Equity ratio in % 33.64 38.46 40.25 40.80 71.45 88.85 95.29
Debt ratio in % 66.36 61.54 59.75 59.20 28.55 11.15 4.71

Mirum Pharmaceuticals Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Ramasastry Saira 06/02/2025 2,500.00 n/a 45.74 Sell No
Ramasastry Saira 06/02/2025 2,500.00 2,500.00 14.12 Buy No
Ramasastry Saira 06/01/2025 5,703.00 n/a 46.20 Sell No
Ramasastry Saira 05/28/2025 5,703.00 5,703.00 n/a Buy No
Howe Jolanda 03/17/2025 2,415.00 2,426.00 44.45 Sell No
Radovich Peter 03/16/2025 7,879.00 18,672.00 44.21 Sell No
Howe Jolanda 03/16/2025 2,900.00 6,647.00 44.21 Sell No
Howe Jolanda 03/16/2025 2,789.00 6,647.00 44.75 Sell No
Howe Jolanda 03/16/2025 1,806.00 4,841.00 44.36 Sell No
Howe Jolanda 03/16/2025 50,111.00 9,436.00 44.33 Sell No
Peetz Christopher 03/16/2025 27,279.00 138,641.00 44.21 Sell No
Heron Patrick J 03/16/2025 21.00 168,672.00 43.93 Buy No
Howe Jolanda 03/16/2025 52,900.00 59,547.00 2.94 Buy No
Radovich Peter 03/14/2025 14,440.00 26,551.00 n/a Buy No
Howe Jolanda 03/14/2025 5,315.00 9,547.00 n/a Buy No
Peetz Christopher 03/14/2025 50,000.00 165,920.00 n/a Buy No
Heron Patrick J 03/13/2025 528.00 168,651.00 44.11 Buy No
Heron Patrick J 03/10/2025 963.00 168,123.00 43.77 Buy No
Heron Patrick J 03/09/2025 758.00 166,583.00 42.66 Buy No
Heron Patrick J 03/09/2025 577.00 167,160.00 43.37 Buy No
Heron Patrick J 03/06/2025 580.00 165,825.00 43.21 Buy No
Heron Patrick J 03/05/2025 1,335.00 165,245.00 43.89 Buy No
Heron Patrick J 03/04/2025 267.00 163,910.00 44.55 Buy No
Radovich Peter 03/03/2025 1,169.00 12,111.00 45.74 Sell No
Radovich Peter 03/03/2025 13,681.00 13,280.00 45.57 Sell No

Mirum Pharmaceuticals Dividend Calendar

Date Name Dividend *yield Currency
2024 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv 0.00 0.00 USD
2023 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv 0.00 0.00 USD
2022 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv 0.00 0.00 USD
2021 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv 0.00 0.00 USD
2020 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv 0.00 0.00 USD
2019 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv 0.00 0.00 USD
2018 Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv - - USD
*Yield of the Respective Date

Mirum Pharmaceuticals Calendar

Event Estimate Info Date
Earnings Report -0.331 USD Q2 2025 Earnings Release 07/31/2025
Earnings Report -0.282 USD Q3 2025 Earnings Release 11/12/2025
Earnings Report -0.271 USD Q4 2025 Earnings Release 03/11/2026
Earnings Report -0.252 USD Q1 2026 Earnings Release 05/13/2026

Mirum Pharmaceuticals Past Events

Event Actual EPS Info Date
Annual General Meeting -1.850 USD Annual General Meeting 05/29/2025
Earnings Report -0.300 USD Q1 2025 Earnings Release 05/07/2025
Earnings Report -0.490 USD Q4 2024 Earnings Release 02/26/2025
Earnings Report -0.300 USD Q3 2024 Earnings Release 11/12/2024
Earnings Report -0.520 USD Q2 2024 Earnings Release 08/07/2024
Annual General Meeting -4.000 USD Annual General Meeting 06/05/2024
Earnings Report -0.540 USD Q1 2024 Earnings Release 05/08/2024
Earnings Report -0.720 USD Q4 2023 Earnings Release 02/28/2024
Earnings Report -0.570 USD Q3 2023 Earnings Release 11/02/2023
Earnings Report -1.940 USD Q2 2023 Earnings Release 08/03/2023
Annual General Meeting -4.010 USD Annual General Meeting 06/12/2023
Earnings Report -0.800 USD Q1 2023 Earnings Release 05/04/2023
Earnings Report -0.980 USD Q4 2022 Earnings Release 03/08/2023
Earnings Report -1.020 USD Q3 2022 Earnings Release 11/09/2022
Earnings Report -0.840 USD Q2 2022 Earnings Release 08/04/2022
Annual General Meeting -2.770 USD Annual General Meeting 06/02/2022
Earnings Report -1.170 USD Q1 2022 Earnings Release 05/05/2022
Earnings Report 1.882 USD Q4 2021 Earnings Release 03/09/2022

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
8
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.